Karyopharm Therapeutics (NASDAQ:KPTI)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a note issued to investors on Tuesday. They currently have a $23.00 price objective on the stock. HC Wainwright’s price objective suggests a potential upside of 118.84% from the company’s previous close.

Other research analysts have also recently issued reports about the stock. Royal Bank of Canada reiterated a “buy” rating and set a $15.00 price objective on shares of Karyopharm Therapeutics in a report on Friday, November 3rd. Robert W. Baird reissued a “buy” rating on shares of Karyopharm Therapeutics in a research report on Friday, November 3rd. Jefferies Group reissued a “buy” rating on shares of Karyopharm Therapeutics in a research report on Friday, October 13th. Cantor Fitzgerald set a $18.00 price target on shares of Karyopharm Therapeutics and gave the company a “buy” rating in a research report on Thursday, October 12th. Finally, initiated coverage on shares of Karyopharm Therapeutics in a research report on Wednesday, November 15th. They set a “buy” rating and a $23.00 price target on the stock. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $17.33.

Shares of Karyopharm Therapeutics (NASDAQ KPTI) opened at $10.51 on Tuesday. Karyopharm Therapeutics has a twelve month low of $7.48 and a twelve month high of $14.63.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings results on Thursday, November 2nd. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.01). Karyopharm Therapeutics had a negative return on equity of 76.83% and a negative net margin of 67,267.47%. research analysts anticipate that Karyopharm Therapeutics will post -2.59 earnings per share for the current fiscal year.

In related news, insider Sharon Shacham sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, December 7th. The shares were sold at an average price of $10.39, for a total transaction of $103,900.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Mansoor Raza Mirza sold 2,882 shares of the business’s stock in a transaction that occurred on Friday, September 15th. The shares were sold at an average price of $11.00, for a total transaction of $31,702.00. Following the transaction, the director now directly owns 2,882 shares of the company’s stock, valued at approximately $31,702. The disclosure for this sale can be found here. In the last ninety days, insiders sold 23,340 shares of company stock worth $255,380. Insiders own 14.71% of the company’s stock.

Large investors have recently modified their holdings of the stock. Swiss National Bank grew its stake in Karyopharm Therapeutics by 39.2% during the second quarter. Swiss National Bank now owns 56,850 shares of the company’s stock valued at $514,000 after acquiring an additional 16,000 shares in the last quarter. Schwab Charles Investment Management Inc. grew its stake in Karyopharm Therapeutics by 4.5% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 86,514 shares of the company’s stock worth $1,111,000 after buying an additional 3,762 shares in the last quarter. Candriam Luxembourg S.C.A. grew its stake in Karyopharm Therapeutics by 16.4% in the 3rd quarter. Candriam Luxembourg S.C.A. now owns 510,000 shares of the company’s stock worth $5,600,000 after buying an additional 72,000 shares in the last quarter. Vanguard Group Inc. grew its stake in Karyopharm Therapeutics by 31.1% in the 2nd quarter. Vanguard Group Inc. now owns 1,621,420 shares of the company’s stock worth $14,675,000 after buying an additional 384,658 shares in the last quarter. Finally, Teachers Advisors LLC grew its stake in Karyopharm Therapeutics by 2.6% in the 2nd quarter. Teachers Advisors LLC now owns 431,350 shares of the company’s stock worth $3,904,000 after buying an additional 10,787 shares in the last quarter. 60.92% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Karyopharm Therapeutics (KPTI) Earns “Buy” Rating from HC Wainwright” was published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/12/12/karyopharm-therapeutics-kpti-earns-buy-rating-from-hc-wainwright.html.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.